The WATERFALL Trial: High-Yield Points
I cannot provide high-yield points from the WATERFALL trial because this trial is not included in the evidence provided to me. None of the studies, guidelines, or drug labels reference a trial called "WATERFALL" related to antiretroviral therapy for HIV infection.
What the Evidence Does Include
The provided evidence contains information about several important HIV treatment trials, but not WATERFALL:
- SPRING-2: Compared dolutegravir vs. raltegravir with 2 NRTIs in treatment-naïve patients 1, 2
- SINGLE: Compared dolutegravir + EPZICOM vs. ATRIPLA in treatment-naïve patients 1, 2
- FLAMINGO: Compared dolutegravir vs. darunavir/ritonavir with NRTIs 2
- SAILING: Evaluated dolutegravir in treatment-experienced, INSTI-naïve patients 1, 2
- VIKING-3: Studied dolutegravir in INSTI-experienced patients with resistance 1, 2
- SWORD-1 and SWORD-2: Evaluated switching to dolutegravir + rilpivirine in virologically suppressed patients 1, 2
- DISCOVER: Compared emtricitabine/tenofovir alafenamide vs. emtricitabine/tenofovir disoproxil fumarate for PrEP 3
Recommendation
If you are seeking information about a specific HIV treatment trial, please verify the trial name or provide additional context about what the WATERFALL trial investigated (e.g., specific drugs, patient population, or outcomes studied). I can then provide relevant information if it exists in available evidence sources.